Company guidance, FDA catalysts, dilution risk and cash runway, built from SEC, FDA and ClinicalTrials.gov filings and updated every day.
$3.5MCash, Pro Forma
30.6mo Cash Runway
Follow ABVC by emailGet an email when ABVC reports key news in an SEC filing, pushes back a promised milestone, files for a stock offering, lands on the Downside Radar or has an FDA decision. Free, no account needed.
We send one confirmation email first. Only emails about ABVC, unsubscribe in one click. Privacy
📄 Latest SEC Filings in Plain English
Nov 13, 2026 ·
Financing Prospectus supplement adds ABVC's Form 10-Q for the quarter ended September 30, 2026, which shows no revenue, a $1,240,593 operating loss for the quarter, and cash and cash equivalents of $11,294. The supplement relates to an offering of 225,500 shares of common stock. Form 424B4 · SEC filing
Nov 13, 2026 ·
Financing Prospectus Supplement No. 7 adds ABVC's 10-Q for the quarter ended September 30, 2026, covering a 1,000,000-share warrant offering. Q3 operating loss was $1,240,593 and cash fell to $11,294. Form 424B4 · SEC filing
Nov 13, 2026 ·
Financing Filed a prospectus supplement attaching its Form 10-Q for the quarter ended September 30, 2026, covering 3,400,187 shares of common stock underlying warrants. The quarter had no revenue, a $1,240,593 operating loss, and $1,124,842 in long-term investment prepayments. Form 424B4 · SEC filing
Nov 13, 2026 ·
Financing Prospectus Supplement No. 7 attaches the Q3 2026 10-Q for ABVC BioPharma, covering 11,714,683 shares of common stock. The 10-Q shows cash of $11,294 at September 30, 2026, against $681,480 at December 31, 2025, and a nine-month operating loss of $3,592,591. Form 424B4 · SEC filing
Nov 10, 2026 ·
Quarterly report for the period ended Sep 30, 2026 Form 10-Q · SEC filing
Nov 2, 2026 ·
Financing Closed a $3.39 million private placement of 17.5% original issue discount senior convertible notes with $4,106,060 principal maturing June 30, 2027. Conversion at 85% of the three-day VWAP with a $0.2 floor. Settling with Lind for a $625,000 payment. Form 8-K · SEC filing · Press release
Sep 29, 2026 ·
Shareholder vote ABVC will hold a virtual special meeting on October 28, 2026 for stockholders to vote on approving its 2026 Equity Incentive Plan, ratifying equity awards granted since February 16, 2026, and authorizing issuance of up to 1,600,653 shares at not less than $1.00 per share for land and property in Taiwan. Form DEF 14A · SEC filing
Aug 27, 2026 ·
Restructuring ABVC completed the separation of BioKey (Cayman), distributing about 15% of its ordinary shares to ABVC common stockholders on August 21, 2026, with ABVC keeping roughly 85% control. BioKey plans an OTC Markets listing, but no trading symbol has been assigned yet. Form 8-K · SEC filing
Each summary is written by AI from the filing itself, and one that names a number or a name the filing does not contain is not shown. Quarterly and annual reports are listed by period. Read the filing before acting on it.
🧪 Trial & FDA Catalysts
Dec 2023 · Phase 2 · Results Expected · PDC-1421 Treatment in Adult Patients With ADHD Registry primary completion date, not a results date
Source: ClinicalTrials.gov trials sponsored by the company, one row per candidate at its most advanced registered trial. FDA approvals: Drugs@FDA. Wrong or missing drug? Report it
💰 Cash Runway & Dilution Risk
ABVC had $94,526 in cash and short-term investments on its Sep 30, 2026 balance sheet.
Including the cash events since then, it holds about $3.5M pro forma, before operating spending after that date:
Closed private placement, announced Nov 2, 2026 (gross proceeds): $3.4M · 8-K
It burns about $341,662/quarter from operations, an estimated runway of 30.6 months from Sep 30, 2026 at that rate (BioRadar estimate, not company guidance).
Dilution pressure:47 · Elevated
Cash runway 31 months (pro forma for cash events since the balance sheet)
ATM program on file since Aug 2026 +15
Shelf registration (S-3, May 2025) +10
Going-concern doubt in the latest 10-Q +15All of these factors raise substantial doubt about the ability of the Company to continue as a going concern.10-Q, Nov 2026
Share count 26,976,625 (latest 10-Q/10-K). Insiders: each officer's, director's and 10% owner's latest Form 3, 4 or 5, direct and indirect shares; options are not counted. 5%+ holders: latest Schedule 13D or 13G of each holder above 5%. Institutions: the total held by all 13F filers (Yahoo Finance); the table lists the largest. Sources have different dates, so the split is approximate. Source: SEC EDGAR.
Get the full ABVC picture
The 7-day free trial adds AI daily briefings, sentiment tracking, trial enrollment progress and email alerts for ABVC and every other ticker you follow. Card required, cancel anytime.
Data: SEC EDGAR, FDA, ClinicalTrials.gov, Yahoo Finance • Informational purposes only, not investment advice. • All tracked stocks A–Z
This data is for informational purposes only, not investment advice. BioRadar does not provide buy/sell recommendations. Past performance does not guarantee future results. Always do your own due diligence.